Symbols / SYRS $0.00 +125.00% Syros Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • PNK
SYRS Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Fundamentals
Scroll to Statements
Market Cap 12.07K Enterprise Value 1.96M Income -97.81M Sales 386.00K Book/sh -0.41 Cash/sh 2.17
Dividend Yield — Payout 0.00% Employees 68 IPO — P/E — Forward P/E -0.00
PEG — P/S 0.03 P/B -0.00 P/C — EV/EBITDA -0.02 EV/Sales 5.09
Quick Ratio 2.05 Current Ratio 2.25 Debt/Eq — LT Debt/Eq — EPS (ttm) -3.07 EPS next Y -2.61
EPS Growth — Revenue Growth — Earnings 2024-10-31 ROA -59.88% ROE -7.77% ROIC —
Gross Margin 0.00% Oper. Margin -288.92% Profit Margin 0.00% Shs Outstand 26.83M Shs Float 26.82M Short Float 3.81%
Short Ratio 0.80 Short Interest — 52W High 0.04 52W Low 0.00 Beta 1.26 Avg Volume 17.21K
Volume 904.00 Target Price $8.75 Recom None Prev Close $0.00 Price $0.00 Change 125.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.75
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-38.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
$4.00
High
$20.00
Mean
$8.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-11-13 down TD Cowen Buy → Hold —
2024-11-13 down HC Wainwright & Co. Buy → Neutral $1
2024-11-13 down JMP Securities Market Outperform → Market Perform —
2024-11-13 down Brookline Capital Buy → Hold —
2024-11-01 reit HC Wainwright & Co. Buy → Buy $6
2024-08-13 reit Piper Sandler Overweight → Overweight $5
2024-08-13 main JMP Securities Market Outperform → Market Outperform $4
2024-08-13 main HC Wainwright & Co. Buy → Buy $6
2024-08-01 reit HC Wainwright & Co. Buy → Buy $15
2024-06-26 reit HC Wainwright & Co. Buy → Buy $15
2024-05-15 reit HC Wainwright & Co. Buy → Buy $15
2024-04-03 reit Piper Sandler Overweight → Overweight $13
2024-04-01 reit HC Wainwright & Co. Buy → Buy $15
2023-10-03 main Piper Sandler Overweight → Overweight $7
2023-08-09 reit HC Wainwright & Co. Buy → Buy $15
2023-05-11 reit HC Wainwright & Co. Buy → Buy $15
2023-05-11 main JMP Securities Market Outperform → Market Outperform $15
2023-03-03 main Oppenheimer — → Outperform $13
2023-03-03 reit HC Wainwright & Co. — → Buy $15
2023-01-05 main Piper Sandler — → Overweight $20
News
RSS: Latest SYRS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-12-02 SIMONIAN NANCY A Director — 37,070 $0.27 $10,016
2024-11-25 SIMONIAN NANCY A Director — 134,713 $0.27 $35,739
2024-11-19 QUIRK GERALD E. Officer — 46,657 $0.28 $12,915
2024-11-18 ROTH DAVID A M.D. Officer — 12,099 $0.20 $2,382
2024-11-18 STEPHENS KRISTIN Officer — 36,133 $0.22 $7,949
2024-11-18 CHEE CONLEY Chief Executive Officer — 134,797 $0.20 $26,932
2024-11-18 HAAS JASON Chief Financial Officer — 137,803 $0.21 $28,980
2024-10-31 ROTH DAVID A M.D. Officer — 18,875 — —
2024-10-31 STEPHENS KRISTIN Officer — 17,000 — —
2024-10-31 CHEE CONLEY Chief Executive Officer — 17,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
9.94
-33.23%
14.88
-36.65%
23.49
Operating Revenue
9.94
-33.23%
14.88
-36.65%
23.49
Operating Expense
136.44
-3.40%
141.24
+14.92%
122.91
Research And Development
108.15
-3.39%
111.94
+12.09%
99.87
Selling General And Administration
28.28
-3.47%
29.30
+27.19%
23.04
General And Administrative Expense
28.28
-3.47%
29.30
+27.19%
23.04
Other Gand A
28.28
-3.47%
29.30
+27.19%
23.04
Total Expenses
136.44
-3.40%
141.24
+14.92%
122.91
Operating Income
-126.50
-0.11%
-126.36
-27.10%
-99.42
Total Operating Income As Reported
-128.99
+5.07%
-135.87
-36.67%
-99.42
EBITDA
-157.19
-79.01%
-87.81
-10.27%
-79.63
Normalized EBITDA
-117.43
+3.37%
-121.53
-26.17%
-96.31
Reconciled Depreciation
2.25
-16.78%
2.71
-10.34%
3.02
EBIT
-159.45
-76.15%
-90.52
-9.52%
-82.65
Total Unusual Items
-39.76
-217.96%
33.71
+102.08%
16.68
Total Unusual Items Excluding Goodwill
-39.76
-217.96%
33.71
+102.08%
16.68
Special Income Charges
-2.49
+73.83%
-9.51
0.00
Restructuring And Mergern Acquisition
2.49
-73.83%
9.51
0.00
Net Income
-164.57
-73.87%
-94.65
-9.35%
-86.56
Pretax Income
-164.57
-73.87%
-94.65
-9.35%
-86.56
Net Non Operating Interest Income Expense
1.69
+184.37%
-2.00
+47.59%
-3.82
Interest Expense Non Operating
5.13
+24.02%
4.13
+5.81%
3.91
Net Interest Income
1.69
+184.37%
-2.00
+47.59%
-3.82
Interest Expense
5.13
+24.02%
4.13
+5.81%
3.91
Interest Income Non Operating
6.82
+219.70%
2.13
+2350.57%
0.09
Interest Income
6.82
+219.70%
2.13
+2350.57%
0.09
Other Income Expense
-39.76
-217.96%
33.71
+102.08%
16.68
Other Non Operating Income Expenses
—
-9.51
—
Gain On Sale Of Security
-37.27
-186.24%
43.22
+159.09%
16.68
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-164.57
-73.87%
-94.65
-9.35%
-86.56
Net Income From Continuing Operation Net Minority Interest
-164.57
-73.87%
-94.65
-9.35%
-86.56
Net Income From Continuing And Discontinued Operation
-164.57
-73.87%
-94.65
-9.35%
-86.56
Net Income Continuous Operations
-164.57
-73.87%
-94.65
-9.35%
-86.56
Normalized Income
-124.81
+2.77%
-128.37
-24.34%
-103.24
Net Income Common Stockholders
-164.57
-73.87%
-94.65
-9.35%
-86.56
Diluted EPS
-5.81
+22.43%
-7.49
+45.88%
-13.84
Basic EPS
-5.81
+22.43%
-7.49
+45.88%
-13.84
Basic Average Shares
28.33
+124.24%
12.63
+102.00%
6.25
Diluted Average Shares
28.33
+124.24%
12.63
+102.00%
6.25
Diluted NI Availto Com Stockholders
-164.57
-73.87%
-94.65
-9.35%
-86.56
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
168.17
-31.21%
244.49
+33.65%
182.94
Current Assets
144.98
-31.42%
211.39
+54.77%
136.59
Cash Cash Equivalents And Short Term Investments
139.53
-31.03%
202.30
+55.18%
130.37
Cash And Cash Equivalents
139.53
-16.68%
167.47
+81.43%
92.30
Other Short Term Investments
0.00
-100.00%
34.84
-8.49%
38.07
Receivables
0.00
-100.00%
1.69
-43.14%
2.98
Accounts Receivable
—
—
0.00
Other Receivables
—
1.69
-43.14%
2.98
Prepaid Assets
—
—
3.24
Other Current Assets
5.45
-26.24%
7.39
+128.42%
3.24
Total Non Current Assets
23.19
-29.91%
33.09
-28.60%
46.35
Net PPE
19.48
-20.99%
24.66
-9.62%
27.29
Gross PPE
27.12
-27.13%
37.22
+0.20%
37.14
Accumulated Depreciation
-7.63
+39.20%
-12.55
-27.38%
-9.86
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
3.27
+5.27%
3.11
+1.87%
3.05
Construction In Progress
—
—
0.00
Other Properties
12.19
-45.72%
22.45
+0.08%
22.43
Leases
11.66
+0.00%
11.66
+0.00%
11.66
Investments And Advances
—
0.00
-100.00%
13.04
Other Non Current Assets
3.71
-56.00%
8.43
+39.94%
6.03
Total Liabilities Net Minority Interest
151.51
+29.77%
116.75
+19.48%
97.72
Current Liabilities
36.68
+19.18%
30.78
-2.32%
31.51
Payables And Accrued Expenses
20.70
+30.60%
15.85
+22.17%
12.97
Payables
11.54
+80.07%
6.41
+73.65%
3.69
Accounts Payable
11.54
+80.07%
6.41
+73.65%
3.69
Current Accrued Expenses
9.15
-3.01%
9.44
+1.69%
9.28
Pensionand Other Post Retirement Benefit Plans Current
6.99
-18.01%
8.53
+34.44%
6.34
Current Debt And Capital Lease Obligation
8.99
+334.14%
2.07
+2.98%
2.01
Current Debt
6.67
—
—
Other Current Borrowings
6.67
—
—
Current Capital Lease Obligation
2.32
+12.22%
2.07
+2.98%
2.01
Current Deferred Liabilities
0.00
-100.00%
4.33
-57.47%
10.18
Current Deferred Revenue
0.00
-100.00%
4.33
-57.47%
10.18
Total Non Current Liabilities Net Minority Interest
114.83
+33.57%
85.97
+29.85%
66.21
Long Term Debt And Capital Lease Obligation
53.08
-13.68%
61.50
-2.66%
63.18
Long Term Debt
34.56
-14.99%
40.65
+0.97%
40.26
Long Term Capital Lease Obligation
18.53
-11.14%
20.85
-9.04%
22.92
Non Current Deferred Liabilities
—
—
0.00
Non Current Deferred Revenue
—
—
0.00
Other Non Current Liabilities
61.75
+152.32%
24.47
+707.92%
3.03
Stockholders Equity
16.66
-86.96%
127.74
+49.89%
85.22
Common Stock Equity
16.66
-86.96%
127.74
+49.89%
85.22
Capital Stock
0.03
+30.00%
0.02
+233.33%
0.01
Common Stock
0.03
+30.00%
0.02
+233.33%
0.01
Preferred Stock
0.00
0.00
0.00
Share Issued
26.45
+30.53%
20.26
+226.70%
6.20
Ordinary Shares Number
26.45
+30.53%
20.26
+226.70%
6.20
Additional Paid In Capital
739.44
+7.81%
685.85
+24.96%
548.87
Retained Earnings
-722.81
-29.48%
-558.23
-20.42%
-463.58
Gains Losses Not Affecting Retained Earnings
0.00
-100.00%
0.10
+229.11%
-0.08
Other Equity Adjustments
—
0.10
+229.11%
-0.08
Total Equity Gross Minority Interest
16.66
-86.96%
127.74
+49.89%
85.22
Total Capitalization
51.22
-69.58%
168.38
+34.20%
125.47
Working Capital
108.30
-40.04%
180.61
+71.89%
105.08
Invested Capital
57.88
-65.62%
168.38
+34.20%
125.47
Total Debt
62.08
-2.35%
63.57
-2.49%
65.19
Capital Lease Obligations
20.85
-9.03%
22.92
-8.07%
24.93
Net Tangible Assets
16.66
-86.96%
127.74
+49.89%
85.22
Tangible Book Value
16.66
-86.96%
127.74
+49.89%
85.22
Available For Sale Securities
—
—
13.04
Derivative Product Liabilities
61.75
+152.32%
24.47
+707.92%
3.03
Investmentin Financial Assets
—
0.00
-100.00%
13.04
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-109.71
+10.85%
-123.06
-23.63%
-99.54
Cash Flow From Continuing Operating Activities
-109.71
+10.85%
-123.06
-23.63%
-99.54
Net Income From Continuing Operations
-164.57
-73.87%
-94.65
-9.35%
-86.56
Depreciation Amortization Depletion
2.25
-16.78%
2.71
-10.34%
3.02
Depreciation
—
2.97
-1.69%
3.02
Depreciation And Amortization
2.25
-16.78%
2.71
-10.34%
3.02
Other Non Cash Items
0.65
-31.79%
0.95
+34.99%
0.71
Stock Based Compensation
10.43
-8.55%
11.41
+10.20%
10.35
Asset Impairment Charge
0.52
0.00
—
Operating Gains Losses
37.27
+197.56%
-38.21
-129.03%
-16.68
Gain Loss On Investment Securities
37.27
+197.56%
-38.21
-129.03%
-16.68
Gain Loss On Sale Of PPE
—
—
0.00
Change In Working Capital
5.05
+191.63%
-5.52
+47.96%
-10.60
Change In Receivables
1.69
+31.83%
1.28
+298.30%
-0.65
Changes In Account Receivables
—
0.00
-100.00%
0.01
Change In Prepaid Assets
1.94
+169.11%
-2.81
-182.11%
-0.99
Change In Payables And Accrued Expense
2.95
-42.20%
5.11
+4.78%
4.88
Change In Accrued Expense
-2.18
-192.92%
2.35
-51.45%
4.83
Change In Payable
5.13
+85.57%
2.77
+5662.50%
0.05
Change In Account Payable
5.13
+85.57%
2.77
+5662.50%
0.05
Change In Other Working Capital
-4.33
+26.00%
-5.85
+53.71%
-12.64
Change In Other Current Assets
3.76
+256.04%
-2.41
-101.25%
-1.20
Change In Other Current Liabilities
-0.96
-13.09%
-0.85
—
Investing Cash Flow
37.34
-44.43%
67.19
+227.60%
-52.65
Cash Flow From Continuing Investing Activities
37.34
-44.43%
67.19
+227.60%
-52.65
Net PPE Purchase And Sale
1.29
+203.79%
-1.24
+0.32%
-1.25
Purchase Of PPE
-0.27
+78.08%
-1.24
+0.32%
-1.25
Sale Of PPE
1.56
0.00
0.00
Capital Expenditure
-0.27
+78.08%
-1.24
+0.32%
-1.25
Net Investment Purchase And Sale
36.05
-47.32%
68.43
+233.10%
-51.41
Purchase Of Investment
-50.97
0.00
+100.00%
-51.41
Sale Of Investment
87.02
+27.17%
68.43
0.00
Financing Cash Flow
43.46
-66.83%
131.04
+85.85%
70.51
Cash Flow From Continuing Financing Activities
43.46
-66.83%
131.04
+85.85%
70.51
Net Issuance Payments Of Debt
-0.07
+77.66%
-0.29
-9.81%
-0.27
Issuance Of Debt
—
0.00
0.00
Repayment Of Debt
-0.07
+77.66%
-0.29
-9.81%
-0.27
Long Term Debt Issuance
—
0.00
0.00
Long Term Debt Payments
-0.07
+77.66%
-0.29
-9.81%
-0.27
Net Long Term Debt Issuance
-0.07
+77.66%
-0.29
-9.81%
-0.27
Net Common Stock Issuance
43.27
-63.85%
119.68
+70.15%
70.34
Common Stock Payments
0.00
+100.00%
-0.08
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.08
—
Proceeds From Stock Option Exercised
0.26
+17.89%
0.22
-54.58%
0.48
Net Other Financing Charges
—
11.44
+27997.56%
-0.04
Changes In Cash
-28.91
-138.46%
75.17
+192.02%
-81.68
Beginning Cash Position
170.55
+78.80%
95.39
-46.13%
177.07
End Cash Position
141.65
-16.95%
170.55
+78.80%
95.39
Free Cash Flow
-109.98
+11.53%
-124.31
-23.34%
-100.78
Interest Paid Supplemental Data
4.55
+33.57%
3.41
+6.80%
3.19
Income Tax Paid Supplemental Data
0.00
0.00
0.00
Amortization Of Securities
-1.31
-640.74%
0.24
+8.48%
0.22
Common Stock Issuance
43.27
-63.87%
119.76
+70.27%
70.34
Issuance Of Capital Stock
43.27
-63.87%
119.76
+70.27%
70.34
Net Preferred Stock Issuance
—
—
0.00
Preferred Stock Issuance
—
—
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category